Borsetto D, et al. Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients. Rhinology. 2020;58(5):430–6. https://www.ncbi.nlm.nih.gov/pubmed/32626853.

CAS  PubMed  Google Scholar 

Hopkins C, Surda P. and N. Kumar Presentation of new onset anosmia during the COVID-19 pandemic Rhinology 2020 58 (3) 295–8 https://www.ncbi.nlm.nih.gov/pubmed/32277751

Whitcroft KL, et al. Position paper on olfactory dysfunction: 2023. Rhinology. 2023;61(33):1–108. https://www.ncbi.nlm.nih.gov/pubmed/37454287.

Article  CAS  PubMed  Google Scholar 

Maniaci A, Lechien JR, Vaira LA. and L. La Via taste and Smell disorders: a critical look at olfactory and gustatory dysfunction life (Basel) 2024 14 (3) https://www.ncbi.nlm.nih.gov/pubmed/38541627

Yang J. and J. M. Pinto the epidemiology of olfactory disorders Curr Otorhinolaryngol Rep 2016 4 (2) 130–41 https://www.ncbi.nlm.nih.gov/pubmed/30613439

Mullol J, et al. Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open. 2012;2(6). https://www.ncbi.nlm.nih.gov/pubmed/23135536.

Dalton P. Olfaction and anosmia in rhinosinusitis. Curr Allergy Asthma Rep. 2004;4(3):230–6. https://www.ncbi.nlm.nih.gov/pubmed/15056406.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, et al. Endotypes of chronic rhinosinusitis based on inflammatory and remodeling factors. J Allergy Clin Immunol. 2023;151(2):458–68. https://www.ncbi.nlm.nih.gov/pubmed/36272582.

Article  CAS  PubMed  Google Scholar 

Fokkens WJ, et al. European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1–464. https://www.ncbi.nlm.nih.gov/pubmed/32077450.

PubMed  Google Scholar 

Fokkens WJ et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with nasal polyps 2023 Rhinology 2023 61 (3) 194–202 https://www.ncbi.nlm.nih.gov/pubmed/36999780

Lee L, Luke L, Boak D. and C. Philpott Impact of olfactory disorders on personal safety and well-being: a cross-sectional observational study Eur Arch Otorhinolaryngol 2024 https://www.ncbi.nlm.nih.gov/pubmed/38396298

Stevens WW et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis J Allergy Clin Immunol Pract 2019 7 (8) 2812–2820 e3 https://www.ncbi.nlm.nih.gov/pubmed/31128376

Ahmed OG. and N. R. Rowan Olfactory Dysfunction and chronic Rhinosinusitis Immunol Allergy Clin North am 2020 40 (2) 223–32 https://www.ncbi.nlm.nih.gov/pubmed/32278447

Qureshi HA. and A. P. Lane Olfaction now and in the future in CRSwNP. Am J Rhinol Allergy 2023 37 (2) 168–74 https://www.ncbi.nlm.nih.gov/pubmed/36848279

Macchi A et al. Sense of smell in chronic rhinosinusitis: a multicentric study on 811 patients Front Allergy 2023 4 1083964 https://www.ncbi.nlm.nih.gov/pubmed/37152304

Hummel T, Kobal G, Gudziol H. and A. Mackay-Sim Normative data for the Sniffin’ Sticks including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects Eur Arch Otorhinolaryngol 2007 264 (3) 237–43 https://www.ncbi.nlm.nih.gov/pubmed/17021776

Brumm MC et al. Updated percentiles for the University of Pennsylvania Smell Identification Test in adults 50 years of age and older Neurology 2023 100 (16) e1691–701 https://www.ncbi.nlm.nih.gov/pubmed/36849448

Ogihara H, Kobayashi M, Nishida K, Kitano M. and K. Takeuchi Applicability of the cross-culturally modified University of Pennsylvania Smell Identification Test in a Japanese population. Am J Rhinol Allergy 2011 25 (6) 404–10 https://www.ncbi.nlm.nih.gov/pubmed/22185745

Jiang RS, Kuo LT, Wu SH, Su MC. Liang Validation of the applicability of the traditional Chinese version of the University of Pennsylvania Smell Identification Test in patients with chronic rhinosinusitis Allergy Rhinol. (Providence). 2014;5(1):28–35. https://www.ncbi.nlm.nih.gov/pubmed/25199144.

Google Scholar 

Altundag A, et al. Cross-culturally modified University of Pennsylvania Smell Identification Test for a Turkish population. Am J Rhinol Allergy. 2015;29(5):e138–41. https://www.ncbi.nlm.nih.gov/pubmed/26358338.

Article  PubMed  Google Scholar 

Alsaleh S et al. Cross-cultural modification of the University of Pennsylvania smell identification test for the Saudi Arabian population: validation and normative values. Saudi Med J 2024 45 (1) 79–85 https://www.ncbi.nlm.nih.gov/pubmed/38220245

Fornazieri MA, Doty RL, Santos CA, Pinna Fde R, Bezerra TF, Voegels RL. (Sao Paulo). 2013;68(1):65–8. https://www.ncbi.nlm.nih.gov/pubmed/23420159. A new cultural adaptation of the University of Pennsylvania Smell Identification Test Clinics.

Picillo M, et al. Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects. Clin Otolaryngol. 2014;39(1):53–7. https://www.ncbi.nlm.nih.gov/pubmed/24373213.

Article  CAS  PubMed  Google Scholar 

Alobid I, et al. Validation of Visual Analogue Scale for loss of smell as a quick test in chronic rhinosinusitis with nasal polyps. J Investig Allergol Clin Immunol. 2023;0. https://www.ncbi.nlm.nih.gov/pubmed/37675801.

Dietz de Loos DAE, Cornet ME, Hopkins C, Fokkens WJ. and S. Reitsma measuring control of disease in Chronic Rhinosinusitis; assessing the correlation between SinoNasal Outcome Test-22 and Visual Analogue Scale item scores Rhinology 2023 61 (1) 39–46 https://www.ncbi.nlm.nih.gov/pubmed/36240497

Hellings PW, et al. EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care. Allergy. 2024;79(5):1123–33. https://www.ncbi.nlm.nih.gov/pubmed/38108602.

Article  PubMed  Google Scholar 

Orlandi RR et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021 Int Forum Allergy Rhinol 2021 11 (3) 213–739 https://www.ncbi.nlm.nih.gov/pubmed/33236525

Mygind N et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol 2001 108 (1 Suppl) S16-25 https://www.ncbi.nlm.nih.gov/pubmed/11449202

Bognanni A et al. Topical corticosteroids for chronic rhinosinusitis with nasal polyposis: GRADE systematic review and network meta-analysis. J Allergy Clin Immunol 2022 150 (6) 1447–59 https://www.ncbi.nlm.nih.gov/pubmed/35970310

Chong LY, Head K, Hopkins C, Philpott C, Schilder AG. and M. J. Burton Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev 2016 4 (4) CD011996 https://www.ncbi.nlm.nih.gov/pubmed/27115217

Wu D, Huang T. and Y. Wei effects of Fluticasone Exhalation Delivery System in patients with chronic Rhinosinusitis with nasal polyps: a systematic review. Am J Rhinol Allergy 2022 36 (2) 176–84 https://www.ncbi.nlm.nih.gov/pubmed/34342516

Calvo-Henriquez C, et al. The role of corticosteroid nasal irrigations in the management of Chronic Rhinosinusitis: a state-of-the-art systematic review. J Clin Med. 2023;12(10). https://www.ncbi.nlm.nih.gov/pubmed/37240711.

Van Gerven L, Langdon C, Cordero A, Cardelus S, Mullol J. and I. Alobid lack of long-term add-on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps laryngoscope 2018 128 (8) 1743–51 https://www.ncbi.nlm.nih.gov/pubmed/29114894

Kern RC et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol 2018 8 (4) 471–81 https://www.ncbi.nlm.nih.gov/pubmed/29350840

Chong LY, Head K, Hopkins C, Philpott C, Burton MJ. and A. G. Schilder different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev 2016 4 (4) CD011993 https://www.ncbi.nlm.nih.gov/pubmed/27115215

Banglawala SM, Oyer SL, Lohia S, Psaltis AJ, Soler ZM. Schlosser olfactory outcomes in chronic rhinosinusitis with nasal polyposis after medical treatments: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2014;4(12):986–94. https://www.ncbi.nlm.nih.gov/pubmed/25400017.

Article  PubMed  Google Scholar 

Van Zele T, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069–76. https://www.ncbi.nlm.nih.gov/pubmed/20451040.

Article  CAS  PubMed  Google Scholar 

Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects, in StatPearls. Treasure Island (FL); 2024.

Hox V et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper Clin Transl Allergy 2020 10 1 https://www.ncbi.nlm.nih.gov/pubmed/31908763

Zhao R, Chen K. and Y. Tang olfactory changes after endoscopic sinus surgery for chronic rhinosinusitis: a meta-analysis Clin Otolaryngol 2021 46 (1) 41–51 https://www.ncbi.nlm.nih.gov/pubmed/32865350

Prasad S, Fong E. and E. H. Ooi systematic review of patient-reported outcomes after revision endoscopic sinus surgery. Am J Rhinol Allergy 2017 31 (4) 248–55 https://www.ncbi.nlm.nih.gov/pubmed/28716176

Rimmer J, Fokkens W, Chong LY. and C. Hopkins Surgical versus medical interventions for chronic rhinosinusitis with nasal polyps. Cochrane Database Syst Rev 2014 2014 (12) CD006991 https://www.ncbi.nlm.nih.gov/pubmed/25437000

Novarria GA, Vultaggio F, Saginario V, Felisati G. and A. M. Saibene Efficacy and safety of middle turbinate surgery: a systematic review. Eur Arch Otorhinolaryngol 2024 https://www.ncbi.nlm.nih.gov/pubmed/38992192

Lourijsen ES et al. Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial. Lancet Respir Med 2022 10 (4) 337–46 https://www.ncbi.nlm.nih.gov/pubmed/35012708

Haxel BR, Boessert P, Weyer-Elberich V. and K. Fruth Course of olfaction after sinus surgery for chronic rhinosinusitis laryngoscope Investig Otolaryngol 2017 2 (5) 269–75 https://www.ncbi.nlm.nih.gov/pubmed/29094070

Calus L et al. Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clin Transl Allergy 2019 9 30 https://www.ncbi.nlm.nih.gov/pubmed/31249662

Arancibia C, Langdon C, Mullol J. and I. Alobid twelve-year long-term postoperative outcomes in patients with chronic rhinosinusitis with nasal polyps Rhinology 2022 60 (4) 261–9 https://www.ncbi.nlm.nih.gov/pubmed/35934318

Rodriguez-Van Strahlen C, Arancibia C, Calvo-Henriquez C, Mullol J. and I. Alobid systematic review of Long Term Sinonasal outcomes in CRSwNP after endoscopic sinus surgery: a call for unified and standardized criteria and terms Curr Allergy Asthma Rep 2024 24 (8) 443–56 https://www.ncbi.nlm.nih.gov/pubmed/38913122

Hsu CY, Wang YP, Shen PH, Weitzel EK, Lai JT. and P. J. Wormald Objective olfactory outcomes after revision endoscopic sinus surgery. Am J Rhinol Allergy 2013 27 (4) e96–100 https://www.ncbi.nlm.nih.gov/pubmed/23883800

Mullol J et al. Olfactory outcomes with Dupilumab in Chronic Rhinosinusitis with nasal polyps J Allergy Clin Immunol Pract 2022 10 (4) 1086–95 e5 https://www.ncbi.nlm.nih.gov/pubmed/34628065

Bachert C et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials Lancet 2019 394 (10209) 1638–50 https://www.ncbi.nlm.nih.gov/pubmed/31543428

Lee SE et al. The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP Rhinology 2023 61 (6) 531–40 https://www.ncbi.nlm.nih.gov/pubmed/37453138

Albrecht T, Sailer MM, Capitani F, van Schaik C, Lowenheim H. and S. Becker Real-World evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy. World Allergy Organ J 2023 16 (5) 100780 https://www.ncbi.nlm.nih.gov/pubmed/37234094

Galletti C et al. Dupilumab in chronic rhinosinusitis with nasal polyps: real life data in a multicentric sicilian experience. Am J Otolaryngol 2024 45 (1) 104106 https://www.ncbi.nlm.nih.gov/pubmed/37948824

van der Lans RJL, Fokkens WJ, Adriaensen G, Hoven DR, Drubbel JJ. and S. Reitsma Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps Allergy 2022 77 (2) 670–4 https://www.ncbi.nlm.nih.gov/pubmed/34626497

Gudziol V, Lotsch J, Hahner A, Zahnert T. and T. Hummel Clinical significance of results from olfactory testing laryngoscope 2006 116 (10) 1858–63 https://www.ncbi.nlm.nih.gov/pubmed/17003712

van der Lans RJL et al. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months Allergy 2023 78 (10) 2684–97 https://www.ncbi.nlm.nih.gov/pubmed/37394895

Otten JJ et al. Steroid responsiveness predicts olfactory function recovery in dupilumab treated CRSwNP Rhinology 2024 https://www.ncbi.nlm.nih.gov/pubmed/38775362

Cantone E et al. Olfaction recovery following Dupilumab is Independent of Nasal Polyp reduction in CRSwNP. J Pers Med 2022 12 (8) https://www.ncbi.nlm.nih.gov/pubmed/35893310

Wu Q et al. Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials BMJ Open 2021 11 (9) e047344 https://www.ncbi.nlm.nih.gov/pubmed/34479933

Gevaert P et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020 146 (3) 595–605 https://www.ncbi.nlm.nih.gov/pubmed/32524991

Mahadev A, Kallogjeri D. and J. F. Piccirillo Validation of Minimal clinically important difference (MCID) for University of Pennsylvania Smell Identification Test (UPSIT). Am J Rhinol Allergy 2024 38 (2) 123–32 https://www.ncbi.nlm.nih.gov/pubmed/38055971

Gevaert P et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol 2022 149 (3) 957–65 e3 https://www.ncbi.nlm.nih.gov/pubmed/34530020

T. S. Tat Omalizumab is effective in nasal polyposis with or without asthma, a real-life study. World Allergy Organ J 2022 15 (8) 100670 https://www.ncbi.nlm.nih.gov/pubmed/36017064

Zheng M et al. Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers - a real-life prospective study. World Allergy Organ J 2022 15 (10) 100702 https://www.ncbi.nlm.nih.gov/pubmed/36254182

Han JK et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet. Respir Med 2021 9 (10) 1141–53 https://www.ncbi.nlm.nih.gov/pubmed/33872587

Gallo S et al. Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a Multicentric Real-Life Study. J Pers Med 2022 12 (8) https://www.ncbi.nlm.nih.gov/pubmed/36013253

Dominguez-Sosa MS et al. Real-life effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with nasal polyps Biomedicines 2023 11 (2) https://www.ncbi.nlm.nih.gov/pubmed/36831021

Forster-Ruhrmann U et al. A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics. World Allergy Organ J 2023 16 (2) 100746 https://www.ncbi.nlm.nih.gov/pubmed/36852411

Mullol J et al. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE Rhinology 2024 https://www.ncbi.nlm.nih.gov/pubmed/38217844

Kariyawasam HH et al. Biologic treatment for severe chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis Rhinology 2023 61 (2) 98–107 https://www.ncbi.nlm.nih.gov/pubmed/37023247

Wu Q et al. Which is the best biologic for nasal polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis. Int Arch Allergy Immunol 2022 183 (3) 279–88 https://www.ncbi.nlm.nih.gov/pubmed/34607329

Agache I et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines Allergy 2021 76 (8) 2337–53 https://www.ncbi.nlm.nih.gov/pubmed/33683704

Papacharalampous GX, Constantinidis J, Fotiadis G, Zhang N, Bachert C. and M. Katotomichelakis Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacy. Int Forum Allergy Rhinol 2024 14 (1) 96–109 https://www.ncbi.nlm.nih.gov/pubmed/37394893

Peters AT et al. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with nasal polyps J Allergy Clin Immunol Pract 2021 9 (6) 2461–71 e5 https://www.ncbi.nlm.nih.gov/pubmed/33548517

Lipworth BJ. and R. Chan the Choice of Biologics in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 2021 9 (12) 4235–8 https://www.ncbi.nlm.nih.gov/pubmed/34332173

Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R. and D. K. Chu comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol 2022 149 (4) 1286–95 https://www.ncbi.nlm.nih.gov/pubmed/34543652

Philpott C et al. Developing a core outcome set for clinical trials in olfactory disorders: a COMET initiative Rhinology 2023 61 (4) 312–9 https://www.ncbi.nlm.nih.gov/pubmed/37243690